Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970477 | 0.83 | TLR4 (0.43) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL28531536 | 0.83 | TLR4 (0.44) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL21218154 | 0.83 | TLR4 (0.44) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL872462 | 0.83 | TLR4 (0.56) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL19797164 | 0.80 | TLR4 (0.42) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL19982521 | 0.78 | TLR4 (0.41) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL19982560 | 0.78 | TLR4 (0.41) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL19982519 | 0.78 | TLR4 (0.41) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL19982456 | 0.74 | TLR4 (0.39) | TLR4TP53MAPTP2RX7LMNA | |
| SCHEMBL19982454 | 0.74 | TLR4 (0.39) | TLR4TP53MAPTP2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109923101-B | Cyclic compound | 武田药品工业株式会社 | 2021-03-09 | — | — | CN | disclosed |
| US-10738004-B2 | Cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-11 | — | — | US | disclosed |
| US-10738004-B2 | Cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-11 | — | — | US | disclosed |
| US-20190233370-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233370-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3511320-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-17 | — | — | EP | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| WO-2018016657-A1 | ETHYL 6-[(2-CHLORO-4-FLUOROPHENYL)METHANESULFONYL]-3-METHYLCYCLOHEX-1-ENE-1-CARBOXYLATE AS TLR4 ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738004-B2 | Cyclic compound | TLR4, TLR3, TLR1 | TLR4 1/4885TP53 1066/4885MAPT 4089/4885 |
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | TLR4 1/4885TP53 562/4885MAPT 3713/4885 |
| US-20190233370-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR6 | TLR4 1/4885TP53 1039/4885MAPT 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.